Cases & Deals

XOMA announces transformational license agreements for Gevokizumab and its IL-1 beta intellectual property portfolio

Clients XOMA Corporation

Jones Day represented XOMA Corporation for its IP due diligence in connection with its license agreements with Novartis for gevokizumab and IL-1 beta IP portfolio.